GLG Partners’s Corbus Pharmaceuticals CRBP Stock Holding History

GLG Partners’s Portfolio CRBP Stock Details CRBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-913	Closed	-$226K	–	348
2017 Q1	$226K	Buy	+913	New	+$224K	0.01%	379

Other funds holding CRBP

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

RJFSA

Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

GLG Partners's CRBP Position: Q2 2017 in Review

GLG Partners sold out of Corbus Pharmaceuticals (CRBP) in Q2 2017, closing a stake of 913 shares — an estimated $226K sold.

GLG Partners first reported a position in CRBP in Q1 2017 and held it in 1 quarter. The position peaked at $226K in Q1 2017. 69 funds tracked by Wall St. Rank hold CRBP as of Q2 2017.

GLG Partners reported no remaining Corbus Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
GLG Partners sold 913 Corbus Pharmaceuticals shares in Q2 2017, an estimated $226K.
GLG Partners first reported a position in Corbus Pharmaceuticals in Q1 2017 and held it in 1 quarter.
GLG Partners's Corbus Pharmaceuticals position peaked at $226K in Q1 2017.
69 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2017.

Based on GLG Partners's 13F filing for Q2 2017, filed 14 Aug 2017.